Designed Biologics Inc.
Designed Biologics Inc.
Science That Supports Innovation.
Experimental Validation That Provides Real Possibilities.
Our technology builds on years of research in protein–protein interactions, computational biology, and peptide engineering.
The following are selected examples of our research, illustrating the established and peer-reviewed utility of our platform:
Precision Targeting of a Disease-Associated Protein.
Published in: Blood Advances | 2026 | Read the Publication: <PubMed>
Here we report on the development of our AI-designed peptide, G14, with an exceptionally high binding affinity of approximately 6.6 picomolar for a disease-associated platelet receptor mutant. The peptide selectively disrupted the abnormal interaction responsible for platelet-type von Willebrand disease without measurable interference with healthy platelet function in the reported experiments.
This research demonstrates the potential to design peptides that distinguish disease-associated proteins from their normal counterparts, an important advance toward precision therapeutics and diagnostics.
AI-Designed Peptides with Anti-Viral Activities Against SARS-CoV-2.
Published in: Nature Communications | 2025 | Read the Publication: <PubMed>
In a study published in Nature Communications, we investigated interactions between SARS-CoV-2 and human proteins across multiple cell types and viral variants. Using computational approaches and deep learning, our research team developed peptide inhibitors that successfully blocked viral entry and replication in laboratory cell models, including against SARS-CoV-2 variants.
The findings demonstrate how computationally designed peptides can be used to disrupt disease-relevant molecular interactions and identify promising candidates for antiviral drug development.
AI-Designed Peptides for COVID-19 Diognastics.
Published in: NAR Genomics and Bioinformatics | 2022 | Read the Publication: <PubMed>
Here we demonstrated the potential of our AI-designed peptides as an alternative to antibodies in protein-based diagnostic assays. Using the eLIFE/InSiPS computational platform, two groups of peptides were designed to recognize different regions of the SARS-CoV-2 spike protein. Their binding capabilities were experimentally validated using ELISA-based assays and surface plasmon resonance. Remarkably, two designed peptides were successfully combined in a sandwich ELISA, with one capturing the target protein and the other detecting it. This system detected spike protein at concentrations as low as 100 pg/mL in laboratory mixtures containing cell lysates.
This study demonstrates the potential to develop highly specific, entirely peptide-based diagnostic systems, opening opportunities for rapid and adaptable detection technologies targeting infectious diseases and other biological markers.
Discovering Functional Peptides in Nature
Published in: International Journal of Molecular Sciences | 2025 | Read the Publication: <PubMed>
Our research has also demonstrated that our AI-designed peptides can help reveal naturally occurring molecules with similar biological activities. By comparing an engineered SARS-CoV-2-binding peptide with sequences found in nature, researchers identified a canola-derived peptide with similar binding and inhibitory functions.
This discovery opens another pathway for identifying functional peptides from natural sources.
Designed Biologics Inc. | Ottawa | Canada